Immune Thrombocytopenic Purpura (ITP) Treatments

Find Immune Thrombocytopenic Purpura (ITP) Treatments

Generic Name

Eltrombopag

Brand Names

Promacta, Eltrombopag Olamine, Alvaiz

FDA approval date: April 01, 2016

Classification: Thrombopoietin Receptor Agonist

Form: Tablet, Powder

What is Promacta (Eltrombopag)?

PROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Enrollment Status: Recruiting

Publish Date: March 11, 2026

Intervention Type: Drug, Procedure

Study Phase: Phase 2

Summary: To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Who is this study for: Child to adult patients with Severe Aplastic Anemia

Enrollment Status: Recruiting

Publish Date: March 09, 2026

Intervention Type: Drug

Study Drugs: Eltrombopag, Cyclosporine, Anti-Thymocyte Globulin

Study Phase: Phase 2

Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine \[CsA\], Eltrombopag \[EPAG\], and horse anti-thymocyte globulin \[h-ATG\]). Researchers want to see if starting people at a lower dose of CsA with EPAG before giving them h-ATG is helpful.

Revolade Tablets Specified Drug-use Survey (Pediatric Aplastic Anemia Naive to Treatment With Anti-thymocyte Immunoglobulin, CETB115G1401)

Enrollment Status: Recruiting

Publish Date: February 19, 2026

Intervention Type: Other

Summary: This is a multicenter, single-arm, non-interventional study (NIS) to confirm the safety and efficacy of eltrombopag in Anti-Thymocyte Globulin (ATG) treatment naive pediatric patients with aplastic anemia (AA).

View All Clinical Trials